NCT05271552View on ClinicalTrials.gov

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

PHASE3CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

April 27, 2022

Primary Completion Date

April 21, 2023

Study Completion Date

April 21, 2023

Conditions
AgitationDementia
Interventions
DRUG

BXCL501

Sublingual Film

DRUG

Matching Placebo

Sublingual Placebo Film

Trial Locations (11)

32117

BioXcel Clinical Research Site, Daytona Beach

32159

BioXcel Clinical Research Site, Lady Lake

32751

BioXcel Clinical Research Site, Maitland

33016

BioXcel Clinical Research Site, Miami Lakes

33161

BioXcel Clinical Research Site, North Miami

70072

BioXcel Clinical Research Site, Marrero

85016

BioXcel Clinical Research Site, Phoenix

90806

BioXcel Clinical Research Site, Long Beach

01103

BioXcel Clinical Research Site, Springfield

08009

BioXcel Clinical Research Site, Berlin

08755

BioXcel Clinical Research Site, Toms River

Sponsors
All Listed Sponsors
collaborator

Cognitive Research Corporation

INDUSTRY

lead

BioXcel Therapeutics Inc

INDUSTRY